Search This Blog

Tuesday, February 25, 2014

Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes (NYSE:LLY)

Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.